Item 5.07. Submission of Matters to a Vote of Security Holders.

AbCellera Biologics Inc. (the "Company") held its Annual Meeting of Shareholders (the "Annual Meeting") on June 15, 2021. As of April 19, 2021, the record date for the Annual Meeting, there were 270,925,888 common shares of the Company outstanding and entitled to vote at the Annual Meeting. The Company's shareholders voted on the following matters, which are described in detail in the Company's Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 28, 2021: (i) to elect Véronique Lecault and John Edward Hamer as Class I directors of the Company to serve for a three-year term expiring at the Company's annual meeting of shareholders in 2024 and until his or her successor has been elected and qualified ("Proposal 1"), and (ii) to ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2021 ("Proposal 2").

The Company's shareholders approved the election of Véronique Lecault and John Edward Hamer as Class I directors recommended for election in Proposal 1 at the Annual Meeting. The Company's shareholders voted for the Class I directors as follows:




                    Nominee            For        Against      Abstain
               Véronique Lecault   157,974,274   10,311,986   1,087,724
               John Edward Hamer   156,787,159   11,335,006   1,251,819

The broker non-votes for this Proposal 1 totaled 12,457,090 common shares.



The Company's shareholders approved Proposal 2. The votes cast at the Annual
Meeting were as follows:


                              For       Against   Abstain
                          181,726,536   62,376    42,162

No other matters were submitted to or voted on by the Company's shareholders at the Annual Meeting.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses